Heart, lipids and blood pressure
What human research has studied for blood lipids, blood pressure and cardiovascular events, across every ingredient in this guide, strongest evidence first. A grade describes the evidence, not a recommendation.
Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. Ask a doctor or pharmacist before use, especially with medicines, in pregnancy or for a child.
How strong the evidence is
Where heart, lipids and blood pressure sits on the supplement body map; colored by its strongest grade here.
Findings by ingredient
| Ingredient | Grade | What was studied and found |
|---|---|---|
| Beta-glucan (oat and barley) | A | LDL cholesterol (oat beta-glucan). A 2016 meta-analysis of 58 RCTs (3,974 participants; median 3.5 g/day, 3 weeks or longer) found oat beta-glucan lowered LDL cholesterol by 0.19 mmol/L, non-HDL cholesterol by 0.20 mmol/L and apoB by 0.03 g/L versus control. sources |
| Beta-glucan (oat and barley) | A | LDL cholesterol (barley beta-glucan). A 2016 meta-analysis of 14 RCTs (615 participants; median 6.5–6.9 g/day for a median 4 weeks) found barley beta-glucan lowered LDL cholesterol by 0.25 mmol/L and non-HDL cholesterol by 0.31 mmol/L; apoB did not change significantly. sources |
| Glucomannan | A | LDL and non-HDL cholesterol. A 2017 meta-analysis of 12 RCTs (370 participants; 8 in adults, 4 in children) found LDL cholesterol fell 0.35 mmol/L and non-HDL 0.32 mmol/L; about 3 g/day lowered them by 10% and 7%. sources |
| Linoleic acid | A | Blood lipids (omega-6 fats overall). The 2018 Cochrane review found high-quality evidence that more omega-6 fat lowers total cholesterol a little (mean -0.33 mmol/L; 10 trials, 4,280 people), with little or no difference in triglycerides, HDL or LDL. sources |
| Niacin (vitamin B3) | A | Blood lipid profile (nicotinic acid). ODS summarizes the trials as showing that nicotinic acid improves blood lipid profiles but has no significant effects on risk of cardiovascular events. sources |
| Omega-3 fatty acids | A | Blood triglyceride levels. A 2020 review of 23 studies (43,998 participants) found EPA and DHA lowered triglycerides by about 15 percent but did not affect body fat or other blood lipids. sources |
| Plant sterols and stanols | A | LDL cholesterol. A 2014 meta-analysis of 124 randomized studies (201 strata) found intakes of 0.6–3.3 g/day lowered LDL cholesterol by 6–12% on average, increasing with dose up to about 3 g/day; sterols and stanols showed comparable dose-response. sources |
| Psyllium | A | LDL cholesterol in adults with or without high cholesterol. Meta-analysis of 28 randomized trials (1,924 participants; median dose ~10.2 g; at least 3 weeks): LDL cholesterol fell by 0.33 mmol/L (95% CI −0.38 to −0.27) versus control; certainty rated moderate. sources |
| Psyllium | A | Non-HDL cholesterol and apolipoprotein B. Same meta-analysis: non-HDL cholesterol fell by 0.39 mmol/L (95% CI −0.50 to −0.27) and apoB by 0.05 g/L (95% CI −0.08 to −0.03); certainty moderate and high. sources |
| Red yeast rice | A | LDL cholesterol. A 2015 meta-analysis of 20 randomized studies of red yeast rice with known monacolin K content found LDL cholesterol fell 1.02 mmol/L versus placebo, similar to statins; safety assessment quality was low in most studies. sources |
| Sodium (electrolytes) | A | Lowering sodium intake: blood pressure and cardiovascular disease. High strength of evidence from randomized trials that reducing sodium intake lowers systolic and diastolic blood pressure; moderate strength for fewer cardiovascular events and less hypertension. sources |
| Algal oil (DHA and EPA) | B | Blood lipids in people without coronary heart disease. A 2012 meta-analysis (11 RCTs, 485 participants) found algal-oil DHA lowered triglycerides (-0.20 mmol/L) and raised HDL (+0.07 mmol/L) and LDL cholesterol (+0.23 mmol/L). sources |
| American ginseng | B | Heart failure (Xinyue Capsule, a saponin extract of American ginseng stems and leaves, added to standard care). A 2025 meta-analysis of nine RCTs (952 patients; one also added a multi-herb capsule) found higher ejection fraction and walking distance and lower BNP/NT-proBNP with add-on saponin; authors advised cautious interpretation. sources |
| Amla | B | Blood lipids and C-reactive protein in adults. A 2023 meta-analysis of nine RCTs (535 adults; 500-1,500 mg/day for 14-84 days) found lower LDL-C (-15.08 mg/dL), triglycerides and hsCRP than placebo; heterogeneity was high and authors urged caution. sources |
| Argan oil | B | Blood lipids. A meta-analysis of 5 randomized trials (292 participants) found lower total cholesterol (−16.85 mg/dl), LDL (−11.67 mg/dl) and triglycerides and higher HDL (+4.14 mg/dl) with argan oil than control. sources |
| Beetroot juice (dietary nitrate) | B | Blood pressure in adults. A meta-analysis of 16 short crossover trials (254 adults, 2 hours to 15 days) found systolic pressure fell 4.4 mm Hg versus placebo; diastolic change was not significant. sources |
| Beetroot juice (dietary nitrate) | B | Blood pressure in people with hypertension. A meta-analysis of 11 randomized trials (349 patients) found clinic systolic pressure fell 5.31 mm Hg versus placebo, with no significant effect on diastolic or 24-hour pressure; certainty was low. sources |
| Berberine | B | Cholesterol. NCCIH reports some evidence that berberine may lower cholesterol. sources |
| Bitter melon | B | Blood lipids. A 2024 meta-analysis of eight RCTs (423 participants) found lower total cholesterol (-9.71 mg/dL) and triglycerides (-10.24 mg/dL), with no significant change in LDL or HDL cholesterol; trials were shorter than 3 months. sources |
| Black seed | B | Blood pressure in adults. A 2023 meta-analysis of randomized trials found systolic pressure 3.06 mmHg and diastolic 2.69 mmHg lower than control, with very high heterogeneity between trials (I² 84.7% and 97.3%). sources |
| Black seed | B | Blood lipids, body weight and other cardiovascular risk factors. A 2025 meta-analysis of 82 studies (5,026 participants; 200–4,600 mg/day for 1–48 weeks) reported improvements in lipids, weight measures, blood pressure, glucose and inflammatory markers. sources |
| Calcium | B | Blood pressure in adults. A Cochrane review (16 trials, 3,048 adults, 1,000–2,000 mg/day) reported systolic blood pressure 1.43 mmHg and diastolic 0.98 mmHg lower than control. sources |
| Chlorella | B | Cholesterol, blood pressure and fasting glucose. 2018 meta-analysis of 19 RCTs (797 participants): total cholesterol −9.09 mg/dL, LDL −8.32 mg/dL, systolic −4.51 mmHg, diastolic −1.64 mmHg, fasting glucose −4.23 mg/dL; triglycerides, HDL and BMI unchanged. sources |
| Chlorella | B | Blood lipids with Chlorella vulgaris. 2022 meta-analysis of 10 RCTs (539 adults): total cholesterol −7.47 mg/dL and LDL −7.71 mg/dL; no significant effect on triglycerides or HDL. Only 2 trials verified supplement content and purity. sources |
| Cocoa flavanols | B | Blood pressure in adults. A 2017 Cochrane review (35 RCTs, 1,804 mainly healthy adults, 2-18 weeks) found a small reduction (about 2 mmHg systolic and diastolic); moderate-quality evidence, with unexplained heterogeneity. sources |
| Cocoa flavanols | B | Blood pressure and vascular function. A 2026 meta-analysis of 25 studies (1,167 participants; 10.6-1,680 mg/day) found systolic -2.73 and diastolic -1.85 mmHg, and better flow-mediated dilation; several authors work for a cocoa-food company. sources |
| Cocoa flavanols | B | Endothelial function (flow-mediated dilation). A 2019 meta-analysis of 15 articles (18 intervention arms) found FMD improved by 1.17%, with an inverted U-shaped dose response; most studies had risk-of-bias concerns. sources |
| Cumin | B | Metabolic syndrome components. A 2025 meta-analysis of 9 RCTs of oral essential oil (8–24 weeks; 2 trials tested caraway or black caraway) in adults with metabolic disorders found lower fasting glucose, triglycerides and waist size and higher HDL; heterogeneity was high. sources |
| Folate (folic acid) | B | Stroke. A Chinese trial in 20,702 adults with hypertension found 800 mcg folic acid plus enalapril lowered stroke risk 21% versus enalapril alone; ODS notes effects appear greater with low folate status. sources |
| Garcinia cambogia | B | Blood lipids. A 2024 meta-analysis of 14 trials (623 subjects) found lower total cholesterol (-6.76 mg/dL) and triglycerides (-24.21 mg/dL) and higher HDL (+2.95 mg/dL); LDL was not significantly affected, and heterogeneity was significant. sources |
| Garlic | B | Total and LDL cholesterol in people with high cholesterol. NCCIH states garlic supplements may reduce total and LDL cholesterol to a small extent. sources |
| Grape seed extract | B | LDL cholesterol and triglycerides. A 2020 review of 11 studies (536 participants) found lower LDL cholesterol and triglycerides but no change in total or HDL cholesterol; studies were small and products varied. sources |
| Grape seed extract | B | Blood pressure. A 2022 review of 19 studies (1,080 participants) found lower diastolic but not systolic blood pressure; results of individual studies differed. sources |
| Green tea | B | Total and LDL cholesterol in adults. A meta-analysis of randomized, placebo-controlled trials, mostly of extract supplements, found small reductions in total and LDL cholesterol and no effect on HDL cholesterol or triglycerides. sources |
| Gymnema | B | Blood lipids and blood pressure. The 2023 Zamani meta-analysis of six randomized trials reported lower triglycerides, total and LDL cholesterol and diastolic blood pressure; the authors cite notable heterogeneity and low study quality. sources |
| Hawthorn | B | Symptoms and exercise capacity in chronic heart failure (NYHA I–III), added to usual care. Cochrane meta-analysis of 10 trials (855 patients): maximal workload rose 5.35 W versus placebo, and shortness of breath and fatigue improved; no relevant mortality or morbidity data were reported, apart from one trial that reported deaths (three hawthorn, one placebo) without further detail. sources |
| Hesperidin | B | Blood lipids. A 2024 meta-analysis of 12 trials (589 participants) found lower LDL (-0.22 mmol/L) and total cholesterol (-0.20 mmol/L), with small changes in fasting glucose, QUICKI, ICAM-1, VCAM-1 and CRP; other risk factors showed no effect. sources |
| Hibiscus (roselle) | B | Blood pressure, lipids and glucose (umbrella review). Pooling 26 randomized trials (1,797 participants), a 2025 umbrella review found dose-dependent reductions in systolic and diastolic pressure versus placebo and other teas, plus lower total and LDL cholesterol and fasting glucose and higher HDL. sources |
| Inulin and FOS | B | LDL cholesterol and triglycerides in adults. A 2024 meta-analysis found inulin-type fructans lowered LDL cholesterol by 0.14 mmol/L (38 RCTs, 1,879 participants; very low certainty) and triglycerides by 0.06 mmol/L (40 RCTs; low certainty); other risk factors changed little. sources |
| Krill oil | B | Blood lipids. A 2017 meta-analysis (7 RCTs, 662 participants) found lower LDL cholesterol (-15.52 mg/dL) and triglycerides (-14.03 mg/dL) and higher HDL (+6.65 mg/dL); the change in total cholesterol was not significant. sources |
| L-arginine | B | Blood pressure in adults. A 2022 meta-analysis of 22 RCTs (30 effect sizes) of oral L-arginine found lower systolic (−6.40 mmHg) and diastolic (−2.64 mmHg) pressure than placebo; no significant change was seen at doses above 9 g/day. sources |
| L-arginine | B | 24-hour ambulatory blood pressure. A 2026 meta-analysis of 5 RCTs (202 participants) reported lower 24-hour systolic (−4.23 mmHg) and diastolic (−3.04 mmHg) pressure with oral L-arginine; the authors note the number of included studies was limited. sources |
| L-carnitine | B | Outcomes after acute myocardial infarction. A meta-analysis of 13 trials (3,629 adults) found lower all-cause mortality, ventricular arrhythmias and new angina, but no effect on heart failure or reinfarction. sources |
| L-citrulline | B | Blood pressure in middle-aged and older adults. A 2025 meta-analysis of 15 RCTs (415 participants) of L-citrulline or watermelon reported lower systolic (−4.02 mmHg) and diastolic (−2.54 mmHg) pressure; the authors rate L-citrulline plus L-arginine superior to L-citrulline or watermelon alone. sources |
| Lactotripeptides (IPP and VPP) | B | Blood pressure in adults. A 2015 meta-analysis of 30 RCTs found systolic -2.95 and diastolic -1.51 mmHg; 24-hour ambulatory pressure did not change significantly, and publication bias and small-study effects weakened the result. sources |
| Lactotripeptides (IPP and VPP) | B | Blood pressure in European adults. A 2013 meta-analysis of 14 trials (15 data sets, 1,306 subjects) found systolic -1.28 mmHg and diastolic -0.59 mmHg versus placebo, with no evidence of publication bias. sources |
| Lactotripeptides (IPP and VPP) | B | Systolic blood pressure in Japanese adults. A 2015 meta-analysis of 18 studies (1,194 subjects) found systolic -5.63 mmHg versus placebo, larger in hypertensive subjects; the authors disclosed industry payment for performing the review. sources |
| Magnesium | B | Blood pressure in adults. A meta-analysis (22 studies, 1,173 adults, 3–24 weeks) reported systolic 3–4 mmHg and diastolic 2–3 mmHg lower; a Cochrane review (12 trials, 545 adults with hypertension) found only a small diastolic reduction. sources |
| Nattokinase | B | Blood pressure in prehypertension or stage 1 hypertension. An 8-week RCT (86 adults, 2,000 FU/day; 73 completed) lowered systolic blood pressure by 5.55 mmHg and diastolic by 2.84 mmHg versus placebo; a 2023 meta-analysis of six RCTs also reported lower blood pressure. sources |
| Notoginseng (san qi) | B | Angina in coronary heart disease (oral preparations added to usual care). A 2013 systematic review of 17 RCTs (1,747 participants) found oral P. notoginseng eased angina symptoms but did not significantly reduce cardiovascular events; small samples and potential bias limited confidence. sources |
| Notoginseng (san qi) | B | Unstable angina (oral Panax notoginseng saponins). A 2018 meta-analysis of 17 RCTs reported fewer and shorter angina attacks and lower nitroglycerin use; authors called for multi-center, large, high-quality trials. sources |
| Notoginseng (san qi) | B | Acute ischemic stroke (Xuesaitong, a Panax notoginseng saponin product, mostly given by intravenous injection). A 2023 meta-analysis of 46 RCTs (7,957 patients; 43 used intravenous injection, 3 oral forms) reported better functional outcomes; certainty was moderate to very low, risk of bias was high, and mortality did not differ. sources |
| Omega-3 fatty acids | B | Major cardiovascular events. Results differ by trial: VITAL (25,871 adults, 1 g/day) found no significant drop in combined major events; REDUCE-IT (8,179, 4 g/day icosapent ethyl) reported 25% fewer; STRENGTH (13,078, 4 g/day) found no significant benefit. sources |
| Pantothenic acid (vitamin B5) | B | Triglycerides (pantethine). A 2005 review of 28 small trials (646 adults; median 900 mg/day, 12.7 weeks) reported triglyceride declines of 14.2% at 1 month and 32.9% at 4 months; a 216-adult trial's declines may partly reflect dietary counseling. sources |
| Pantothenic acid (vitamin B5) | B | LDL and total cholesterol (pantethine). Two randomized placebo-controlled studies (152 adults; 600 then 900 mg/day, 16 weeks, with diet) found small but significant reductions. Pantothenic acid itself does not appear to have the same effects. sources |
| Plant sterols and stanols | B | LDL cholesterol in people taking statins. A European Atherosclerosis Society consensus panel reported that at 2 g/day, plant sterol/stanol LDL lowering is additive to that of statins in people with dyslipidemia, equivalent to doubling the statin dose. sources |
| Pomegranate | B | Blood pressure in adults. A 2024 meta-analysis of 22 RCTs found lower systolic (-7.87 mmHg) and diastolic (-3.23 mmHg) pressure, with very high heterogeneity (I² about 90%); authors called for higher-quality studies. sources |
| Potassium | B | Blood pressure in adults. A meta-analysis (25 RCTs, 1,163 adults with hypertension, 30–120 mmol/day, 4–15 weeks) reported systolic 4.48 and diastolic 2.96 mmHg lower; a Cochrane review of six high-quality trials found nonsignificant reductions. sources |
| Prickly pear | B | Body fat, blood pressure and total cholesterol. The 2015 Onakpoya meta-analysis reported significant reductions in body mass index, percentage body fat, systolic and diastolic blood pressure and total cholesterol, but few trials had been published and their quality was inconsistent. sources |
| Propolis | B | Blood pressure and blood lipids in adults. A 2025 dose-response meta-analysis of randomized trials reported lower triglycerides, LDL cholesterol and systolic blood pressure (-2.24 mmHg) versus control, with no significant effect on total cholesterol or diastolic pressure. sources |
| Purslane | B | Blood lipids and C-reactive protein. A 2023 meta-analysis of 13 RCTs found lower triglycerides (-16.72 mg/dL), total cholesterol (-9.97 mg/dL) and CRP (-1.22 mg/L) and higher HDL (+4.09 mg/dL); LDL was not affected. sources |
| Purslane | B | Blood pressure and body weight. A 2023 meta-analysis of seven RCTs found lower body weight (-0.73 kg), BMI (-0.35 kg/m2) and systolic blood pressure (-3.64 mmHg), with no significant effect on waist circumference or diastolic pressure. sources |
| Quercetin | B | Blood pressure. A 2016 meta-analysis of placebo-controlled RCTs (7 trials, 9 arms, 587 patients) found quercetin lowered systolic BP by 3.04 and diastolic by 2.63 mmHg; significant effects appeared at doses of 500 mg/day or more. sources |
| Red clover | B | Blood lipids in peri- and postmenopausal women. A 2020 meta-analysis of ten studies (910 women) found lower total cholesterol (-0.29 mmol/L) but no significant change in LDL, HDL or triglycerides, with high heterogeneity between studies. sources |
| Resistant starch | B | Total and LDL cholesterol. A 2018 meta-analysis of 20 trials (14 articles) found resistant starch lowered total cholesterol by 7.33 mg/dL and LDL cholesterol by 3.40 mg/dL; effects were clearer with supplementation longer than 4 weeks. sources |
| Safflower | B | Seed oil: LDL and total cholesterol compared with other oils and fats. A 2018 network meta-analysis of 54 randomized trials comparing oils and solid fats ranked safflower oil highest for lowering LDL cholesterol (SUCRA 82%) and total cholesterol (SUCRA 90%). sources |
| Safflower | B | Safflower yellow (a flower pigment preparation, injected in cited trials): acute ischemic stroke. A 2014 systematic review of 7 RCTs (762 participants; cited trial reports describe injections, not oral use) found a higher neurological improvement rate than control; none of the trials was of high methodological quality. sources |
| Sea buckthorn | B | Blood lipids in adults. A meta-analysis of 15 RCTs found lower triglycerides, total and LDL cholesterol and higher HDL; subgroup analysis showed lipid reductions only in people with abnormal lipids. Heterogeneity was high. sources |
| Spirulina | B | Blood lipids in adults. 2023 meta-analysis of 20 trials (23 arms, 1,076 participants): spirulina lowered LDL cholesterol, total cholesterol and triglycerides (each SMD −0.6) and raised HDL (SMD 0.3). sources |
| Spirulina | B | Blood pressure in adults. 2025 meta-analysis of RCTs: systolic −4.41 mmHg and diastolic −2.84 mmHg versus control, with substantial heterogeneity; authors rated certainty moderate and called for more high-quality trials. sources |
| Sumac | B | Blood lipids and blood pressure in adults. A 2025 meta-analysis of 17 trials (1,170 participants, mostly in Iran) found LDL −9.62 mg/dL, triglycerides −8.96 mg/dL, HDL +2.95 mg/dL and diastolic pressure −2.87 mmHg versus control; systolic pressure did not change. sources |
| Taurine | B | Heart rate, blood pressure and heart function. A 2024 meta-analysis of 20 RCTs (808 participants) reported lower heart rate (−3.579 bpm) and systolic pressure (−3.999 mm Hg), and higher LVEF in heart failure; no significant adverse effects versus controls. sources |
| Whey protein | B | Blood pressure in adults. A 2023 meta-analysis of 18 studies (1,177 subjects) found systolic pressure 1.54 mmHg lower with whey, with significant heterogeneity, and no overall change in diastolic pressure. sources |
| Andrographis | C | Triglycerides in adults with modestly raised levels. One trial reported triglyceride reductions with a high-dose extract comparable to gemfibrozil. sources |
| Arjuna | C | Heart failure (as add-on to standard therapy). A 2026 meta-analysis of nine studies (537 patients) found lower left ventricular mass and higher HDL cholesterol, but no significant change in ejection fraction, blood pressure, triglycerides or LDL. sources |
| Arjuna | C | Chronic stable angina. A 2014 systematic review found studies of poor methodological design and no significant difference from control in pooled outcomes; it judged the evidence insufficient for any conclusion. sources |
| Arjuna | C | Cholesterol in coronary heart disease. In a 30-day randomized trial of 105 patients, 500 mg/day bark powder lowered total cholesterol (-9.7%) and LDL (-15.8%) within the group; placebo and vitamin E groups showed no lipid changes. sources |
| Arjuna | C | Blood pressure in stage 1 hypertension. In a 28-day triple-blind RCT of 44 patients on telmisartan, 3 g/day arjuna lowered systolic and diastolic blood pressure more than placebo. sources |
| Arjuna | C | Heart pumping measures in healthy adults. In an 8-week RCT of 72 healthy adults aged 30-70, 400 mg/day of a proprietary aqueous bark extract raised ejection fraction 6.28% from baseline versus 0.24% with placebo; one author reported a company affiliation and personal fees. sources |
| Arjuna | C | Heart measures in young men who exercise. In a 56-day RCT of 32 healthy male endurance exercisers, 400 mg/day of the same proprietary bark extract improved left ventricular ejection fraction versus placebo. sources |
| Aronia (black chokeberry) | C | Cardiometabolic markers in adults (weight, glucose, lipids, blood pressure). A 2025 meta-analysis of 10 placebo-controlled trials (666 participants) found no significant effect on any cardiometabolic outcome; risk of bias was often unclear or high and certainty was very low. sources |
| Astaxanthin | C | Weight, blood pressure, glucose and lipids. 2020 meta-analysis of 14 articles: no effect on glucose, HbA1c, total or LDL cholesterol, triglycerides, weight or blood pressure; HDL rose 1.47 mg/dL; CRP fell only with ≥12 weeks or >12 mg/day. sources |
| Açaí | C | Blood cholesterol and triglycerides. A 2025 meta-analysis (8 studies, 411 participants, including nonrandomized trials) found no significant effect on LDL, HDL, total cholesterol or triglycerides; certainty of evidence was low to very low. sources |
| Baikal skullcap | C | Blood lipids in coronary artery disease with rheumatoid arthritis (purified baicalin). A 12-week placebo-controlled trial in 374 patients found 500 mg/day purified baicalin lowered triglycerides, total cholesterol and hs-CRP; this tested one compound, not the whole herb. sources |
| Berberine | C | Blood pressure (with amlodipine). NCCIH reports berberine may offer additional benefit when combined with the blood pressure drug amlodipine. sources |
| Bromelain | C | Fibrinogen and cardiovascular risk factors. MSK: bromelain does not appear to reduce fibrinogen or influence other cardiovascular disease risk factors. sources |
| Calcium | C | Cardiovascular disease. A 2021 meta-analysis of 13 double-blind, placebo-controlled trials reported a 15% higher risk of cardiovascular disease with calcium supplements (RR 1.15, 95% CI 1.06 to 1.25), specifically in healthy postmenopausal women; other analyses have reached different conclusions, so the question remains unsettled. sources |
| Choline | C | Cardiovascular disease. Large observational studies found no significant link between choline intake and cardiovascular or peripheral artery disease; one analysis of about 120,000 people linked higher intake to higher mortality. sources |
| Chromium | C | Blood lipids. Trials conflict; meta-analyses found no significant change in total or LDL cholesterol, with some HDL increases and triglyceride decreases. sources |
| Cocoa flavanols | C | Cardiovascular events in older adults. COSMOS (21,442 older US adults, 500 mg flavanols/day, median 3.6 years) found no significant reduction in total cardiovascular events (HR 0.90); cardiovascular death was lower (HR 0.73), a secondary endpoint. sources |
| Coenzyme Q10 | C | Heart failure. A 2021 Cochrane review (11 studies, 1,573 people) found moderate-quality evidence of lower mortality and hospitalization, but most trials were small with bias risk; it found no convincing evidence to support or refute use. sources |
| Coenzyme Q10 | C | Blood pressure in primary hypertension. A 2016 Cochrane review (2 pooled RCTs, 50 participants) found moderate-quality evidence of no clinically significant effect on blood pressure; authors said more well-conducted trials are needed because of the small numbers. sources |
| Conjugated linoleic acid (CLA) | C | Blood lipids. NIH ODS states CLA might adversely affect lipid profiles, although study results are inconsistent; some isomers may lower HDL cholesterol and raise lipoprotein(a). sources |
| Copper | C | Cardiovascular disease. Observational studies are mixed (e.g., higher serum copper linked to coronary death in NHANES II), and small supplementation trials showed little effect on markers; ODS finds evidence insufficient to support any conclusions. sources |
| D-ribose | C | Heart function and quality of life in heart failure. A double-blind randomized crossover study in 15 patients with coronary disease and congestive heart failure (3 weeks per period) reported better diastolic echocardiography measures and quality of life with D-ribose than placebo. sources |
| Danshen | C | Acute myocardial infarction (danshen preparations plus usual care). Cochrane (2008): six studies (2,368 participants), most testing multi-herb formulas (per EMA) and only one a genuine RCT; the evidence was too weak to judge effects and the safety of danshen preparations is unproven. sources |
| Ecklonia cava | C | Body fat and blood lipids in overweight adults. In a 12-week RCT of 97 overweight Korean adults, 72 or 144 mg/day polyphenol extract lowered BMI, body fat, waist size, total and LDL cholesterol versus placebo. sources |
| Fucoidan | C | Blood pressure and LDL cholesterol in overweight adults. In overweight or obese adults, fucoidan for 3 months decreased diastolic blood pressure and LDL cholesterol and increased insulin secretion (studies summarized by MSK). sources |
| Garlic | C | Blood pressure in people with high blood pressure. Limited evidence suggests a small reduction. sources |
| Goji | C | Blood lipids with a healthy diet in middle-aged and older adults. In a 16-week trial in 40 adults following healthy-diet advice, adding 15 g/day dried wolfberry raised HDL cholesterol compared with diet alone; other vascular measures did not differ. sources |
| Green tea | C | Coronary heart disease risk. A meta-analysis of cohort (observational) studies linked green tea drinking to lower risk in Asian populations but not in Western populations. sources |
| Guggul | C | Blood cholesterol in adults with high cholesterol (US trial). In a US RCT (103 adults, 8 weeks), guggulipid raised LDL-C by 4-5% while it fell 5% on placebo, with no significant change in other lipids. sources |
| Guggul | C | Blood cholesterol (pooled trials). A 2021 meta-analysis of Ayurvedic herbs reported that guggulu lowered total cholesterol by 16.78 mg/dL and LDL by 18.78 mg/dL; this conflicts with the US trial. sources |
| Guggul | C | Cholesterol with a guggulu-Triphala combination. A 3-month RCT in 90 adults found no advantage over placebo for total or LDL cholesterol, BMI or waist circumference. sources |
| Haritaki | C | Endothelial function in type 2 diabetes. A 12-week RCT in 60 patients found an aqueous extract (250 or 500 mg twice daily) improved endothelial function (reflection index) and other cardiovascular risk markers versus placebo. sources |
| Hawthorn | C | Heart failure outcomes in later research. NCCIH describes the evidence on heart failure as conflicting; one study of a specific preparation suggested a possible early risk of heart failure progression. sources |
| Hawthorn | C | Heart disease, angina, abnormal heartbeat, plaque buildup. NCCIH states there is not enough evidence to know whether hawthorn helps these conditions. sources |
| Hesperidin | C | Blood pressure. A 2019 meta-analysis of 10 RCTs (577 participants) found no effect on systolic (-0.85 mmHg) or diastolic (-0.48 mmHg) blood pressure, or on blood lipids. sources |
| Hibiscus (roselle) | C | Blood pressure in adults with hypertension (Cochrane). A 2021 Cochrane review found only one eligible placebo-controlled trial (60 people with type 2 diabetes, 8 weeks) and judged the evidence insufficient, of very low certainty, to determine an effect on blood pressure. sources |
| Jatamansi (spikenard) | C | Blood pressure in stage 1 hypertension. In a single-blind RCT of 40 adults, 3 g/day for 4 weeks lowered mean blood pressure from about 144/95 to 134/83 mmHg, while placebo produced no significant change. sources |
| Jujube | C | Metabolic syndrome measures. An 8-week trial (30 g/day jujube powder) found no change in fasting glucose, LDL cholesterol or blood pressure, but improved waist size, triglycerides and HDL; authors noted blinding weaknesses. sources |
| Kutki (Picrorhiza) | C | Blood lipids (five-herb combination). A pilot study in 19 patients of a tablet combining garlic, fenugreek, guggul, Picrorhiza (200 mg) and black pepper reported lower total cholesterol and triglycerides; the herb's own effect cannot be separated. sources |
| Linoleic acid | C | All-cause mortality and cardiovascular events. A 2018 Cochrane review found low-quality evidence that more omega-6 fat (12 of 19 trials tested linoleic acid) makes little or no difference to all-cause mortality (10 trials, 4,506 people) or cardiovascular events (7 trials). sources |
| Linoleic acid | C | Replacing saturated fat with linoleic-acid-rich corn oil (Minnesota Coronary Experiment, 1968-73). Recovered data from this double-blind RCT (9,423 adults) showed lower serum cholesterol but no mortality benefit; each 30 mg/dL cholesterol reduction was associated with a 22% higher risk of death. sources |
| Linoleic acid | C | Men after a coronary event: safflower-oil linoleic acid replacing saturated fat (Sydney Diet Heart Study, 1966-73). Recovered data from this RCT (458 men) showed higher death rates with linoleic acid than controls (all-cause 17.6% vs 11.8%; hazard ratio 1.62, 95% CI 1.00 to 2.64). sources |
| Lycopene | C | Cardiovascular risk factors (tomato products and lycopene supplements). A 2017 meta-analysis of 21 intervention trials found lycopene supplementation reduced systolic blood pressure by 5.66 mmHg; tomato interventions reduced LDL cholesterol and IL-6 and improved flow-mediated dilation. sources |
| Lycopene | C | Blood pressure and blood lipids (dietary or supplemental lycopene). A 2020 review of 43 studies (1.44 to 75 mg/day, food or supplement) found no significant differences between lycopene and control groups for blood pressure or lipids; findings across studies conflicted. sources |
| Manuka honey | C | Blood cholesterol. MSK reports that manuka honey did not reduce cholesterol levels in people with hypercholesterolemia. sources |
| Moringa | C | Blood pressure in adults. The 2025 Crișan meta-analysis of nine randomized trials found a modest reduction in diastolic blood pressure that was not robust in sensitivity analyses. sources |
| MSM (methylsulfonylmethane) | C | Blood lipids in overweight and obese adults. In an RCT of 22 overweight or obese adults, 3 g/day MSM for 16 weeks raised HDL cholesterol at 8 and 16 weeks compared with baseline. sources |
| Nattokinase | C | Blood lipids. A 2023 meta-analysis (6 RCTs, 546 participants) found no lipid-lowering effect; with lower total doses, total and LDL cholesterol were higher and HDL cholesterol lower than with control, higher doses also had higher total cholesterol, blood glucose rose slightly, and triglycerides did not differ. sources |
| NMN (nicotinamide mononucleotide) | C | Blood pressure in adults. In the 2026 Yang meta-analysis of 15 randomized trials, systolic blood pressure did not change significantly; diastolic pressure decreased slightly. Larger, longer trials are needed. sources |
| Noni | C | Blood lipids in cigarette smokers. MSK cites a small clinical study suggesting noni juice may lessen smoking-related dyslipidemia; further research is needed to confirm the effect. sources |
| Olive leaf extract | C | Blood pressure in prehypertensive men. Double-blind crossover RCT in 60 men: 6 weeks of extract (136 mg oleuropein daily) lowered daytime and 24-hour systolic and diastolic blood pressure versus control (24-h systolic -3.33 mmHg). sources |
| Olive leaf extract | C | Blood pressure in stage-1 hypertension (versus captopril). In an 8-week double-blind trial, 500 mg extract twice daily lowered systolic pressure by 11.5 mmHg versus 13.7 mmHg with captopril; the difference between groups was not significant. sources |
| Olive leaf extract | C | Blood lipids and blood pressure in overweight adults. In an 8-week RCT of 77 overweight adults with mildly raised cholesterol, 500 mg/day extract did not change lipids, oxidized LDL, blood pressure, glucose or insulin versus placebo. sources |
| Perilla | C | Leaf powder: blood pressure and oxidized LDL. In a 6-month RCT of 60 healthy adults, leaf powder lowered oxidized LDL; home systolic pressure fell more than placebo only in those with prehypertension. sources |
| Plant sterols and stanols | C | Triglycerides in hypertriglyceridemia. The consensus panel described a reported 6–9% triglyceride lowering at 2 g/day in hypertriglyceridemic patients and said it warrants further evaluation. sources |
| Plant sterols and stanols | C | Heart attacks, strokes and other cardiovascular events. The consensus panel states there are no randomized controlled trial data with hard end points to establish clinical benefit from plant sterols or stanols. sources |
| Pomegranate | C | Blood lipids. A 2025 meta-analysis of 37 RCTs (2,695 participants) found HDL cholesterol rose 2.50 mg/dL, with no significant change in total or LDL cholesterol or triglycerides. sources |
| Potassium | C | Stroke. A meta-analysis of 16 cohort studies associated the highest potassium intakes with a 13% lower stroke risk than the lowest (RR 0.87, 95% CI 0.80 to 0.94, adjusted for blood pressure). This is an observational association, not a supplement trial. sources |
| PQQ (pyrroloquinoline quinone) | C | Blood lipids. A 12-week RCT in 29 healthy adults (20 mg/day) found no change in triglycerides and a marginally significant fall in LDL cholesterol, significant only in those with high baseline LDL. sources |
| Prickly pear | C | Blood lipids, fruit versus cladode. A 2020 systematic review of 11 studies found prickly pear fruit was associated with significant total-cholesterol reductions in all but one study, while cladode effects on lipids were small. sources |
| Red yeast rice | C | HDL cholesterol, triglycerides and apolipoproteins. A 2024 meta-analysis of 14 double-blind trials (2012–2022) found red yeast rice extract lowered total and LDL cholesterol but did not significantly change HDL cholesterol, triglycerides or apolipoproteins A-I and B. sources |
| Red yeast rice | C | Products low in monacolin K. NCCIH states it is unknown whether products with very little monacolin K lower cholesterol; some products contain less monacolin K than the level known to lower cholesterol in clinical trials. sources |
| Resveratrol | C | Cardiovascular risk factors. A meta-analysis found no benefit on cardiovascular risk factors; resveratrol did not lower all-cause mortality in older adults, and higher doses may raise cardiovascular risk biomarkers. sources |
| Rooibos | C | Blood lipids and oxidative stress in adults at cardiovascular risk. 40 adults drank six cups of fermented rooibos daily for 6 weeks, compared with a control period: LDL cholesterol and triglycerides fell and HDL rose; the study had no placebo group. sources |
| Rooibos | C | Angiotensin-converting enzyme (ACE) activity in healthy volunteers. In a randomized crossover study of 17 volunteers, a single 400 ml dose of rooibos inhibited ACE activity at 30 and 60 minutes; nitric oxide did not change. Blood pressure was not an outcome. sources |
| Rooibos | C | Heart structure and function in adults at cardiovascular risk. A 12-week randomized, placebo-controlled trial of green and fermented rooibos extract capsules reported mixed echocardiography changes, some also in the placebo group. sources |
| Rose hip | C | Blood pressure and cholesterol in obese adults. In a 6-week crossover RCT of 31 obese adults, a 40 g/day rose hip powder drink lowered systolic blood pressure by 3.4% and total cholesterol by 4.9% versus a control drink; weight and glucose tolerance did not differ. sources |
| Royal jelly | C | Blood cholesterol. MSK reports that some limited human studies suggest improved total and LDL cholesterol in people with moderately elevated levels. sources |
| Sage | C | Blood cholesterol and lipids. NCCIH: a few studies suggest sage may benefit blood cholesterol and other lipids. sources |
| Stevia | C | Blood pressure. A 2019 meta-analysis of nine RCTs (462 participants) called a systolic reduction versus placebo (mean difference -6.32 mm Hg) significant, though its reported confidence interval (-7.69 to 0.46) includes zero; the diastolic change was not significant, and heterogeneity was significant. sources |
| Stevia | C | Blood pressure and fasting glucose (earlier pooled trials). A 2015 meta-analysis (9 studies, 756 participants) found no significant change in systolic pressure but lower diastolic pressure and fasting glucose; effects were small and heterogeneous, and rebaudioside A showed no significant effect. sources |
| Thiamin (vitamin B1) | C | Heart failure (left ventricular ejection fraction). A meta-analysis of two randomized placebo-controlled trials found thiamin improved net change in ejection fraction; the authors did not assess clinical significance. sources |
| Ubiquinol | C | Heart failure with preserved ejection fraction. A 12-week phase 2 RCT (216 patients; ubiquinol 600 mg/day and/or D-ribose 15 g/day, factorial design) reported that ubiquinol and/or D-ribose improved symptom scores, vigor and ejection fraction; 6-minute walk did not improve. sources |
| Vitamin K | C | Coronary artery calcification and heart disease. A 3-year RCT in 388 older adults (500 mcg phylloquinone) found no overall difference in calcification progression; cohort studies linked higher menaquinone intake to lower coronary heart disease mortality. sources |
| Vitamin K2 (menaquinone-7) | C | Coronary artery calcification in symptomatic coronary artery disease. A 2-year RCT (VitaK-CAC; 180 patients randomized, 360 micrograms/day) found slower progression of coronary artery calcium scores with MK-7 than placebo (P = .02); no significant adverse effects were observed. sources |
| Vitamin K2 (menaquinone-7) | C | Arterial calcification in type 2 diabetes with cardiovascular disease. A 6-month RCT (68 patients, 360 micrograms/day) found MK-7 did not reduce femoral arterial calcification; PET-measured activity tended to increase versus placebo (P = 0.06, not significant). sources |
| White mulberry leaf | C | Blood lipids. The 2017 meta-analysis of 13 RCTs found no difference in total cholesterol, triglycerides, LDL or HDL cholesterol. sources |
| Arjuna | X | Chronic heart failure: ejection fraction. In a 12-week double-blind RCT of 100 patients on standard therapy, 750 mg twice daily of a bark water extract did not change ejection fraction or most secondary outcomes versus placebo. sources |
| Folate (folic acid) | X | Cardiovascular disease (other than stroke). Folic acid lowers homocysteine but trials, including one in 5,442 women using 2,500 mcg, found no reduction in major cardiovascular events. sources |
| Krill oil | X | Blood pressure, glycemic control, body composition and inflammatory markers. A 2023 meta-analysis (14 trials, 1,458 participants) found lower total cholesterol, LDL and triglycerides but no effect on blood pressure, glycemic control, body composition or inflammatory markers. sources |
| L-arginine | X | Vascular stiffness and heart function after acute myocardial infarction. In the VINTAGE MI trial (153 patients, 6 months), L-arginine added to standard care did not improve vascular stiffness or ejection fraction; 6 patients (8.6%) on L-arginine died versus none on placebo. sources |
| MCT oil (medium-chain triglycerides) | X | Blood cholesterol and triglycerides. A 2021 meta-analysis of 7 articles reporting randomized trials found MCT oil did not change total, LDL or HDL cholesterol but slightly raised triglycerides (0.14 mmol/L). sources |
| Multivitamin/mineral supplements | X | Cardiovascular events. PHS II (14,641 men, median 11.2 years) and COSMOS (median 3.6 years) found no reduction in major cardiovascular events. sources |
| Nattokinase | X | Progression of subclinical atherosclerosis. A double-blind RCT (NAPS; 265 adults without cardiovascular disease, 2,000 FU/day, median 3 years) found no effect on carotid intima-media thickness or arterial stiffness progression, blood pressure or any laboratory measure. sources |
| Niacin (vitamin B3) | X | Cardiovascular events and mortality (nicotinic acid). A 2017 Cochrane review (23 RCTs, 39,195 participants; median 2 g/day) found no reduction in overall or cardiovascular mortality. HPS2-THRIVE (25,673 adults on statins) and AIM-HIGH (3,414 patients) found no fewer cardiovascular events. sources |
| Quercetin | X | Blood lipids. A meta-analysis of five RCTs (442 subjects) found no clinically relevant effect of quercetin on LDL, HDL or total cholesterol; triglycerides fell only in a higher-dose, longer-duration subgroup. sources |
| Safflower | X | Seed oil replacing saturated fat after a coronary event (Sydney Diet Heart Study). In a randomized trial of 458 men, replacing saturated fats with safflower oil and safflower-oil margarine led to higher death rates from all causes, cardiovascular disease and coronary heart disease than controls. sources |
| Selenium | X | Cardiovascular events. A Cochrane review of SELECT and 11 smaller trials (19,715 participants) found selenium did not reduce fatal or nonfatal cardiovascular events. sources |
| Soy isoflavones | X | Total and LDL cholesterol in menopausal women (isoflavone extract alone). A meta-analysis of randomized placebo-controlled trials (10 and 9 trials) found about 70 mg/day extracted isoflavones alone for 1–3 months did not improve total or LDL cholesterol in normocholesterolemic menopausal women. sources |
| Vitamin B12 | X | Cardiovascular disease. A Cochrane review of 15 studies (71,422 participants) found B12 alone or with other B vitamins did not reduce heart attacks or death rates; B-PROOF follow-up (1,298 participants) found no effect. sources |
| Vitamin B6 | X | Cardiovascular disease. Trials including HOPE 2 (over 5,500 adults), a 5,442-woman trial (50 mg/day with folic acid and B12), Norwegian trials (6,837 patients) and VISP found no effect on cardiovascular events or stroke. sources |
| Vitamin C | X | Cardiovascular disease. The Women's Antioxidant Cardiovascular Study (8,171 women, 500 mg/day, 9.4 years) and Physicians' Health Study II (500 mg/day, 8 years) found no effect on major cardiovascular events. sources |
| Vitamin D | X | Cardiovascular disease. In VITAL (25,871 adults; 2,000 IU/day; median 5.3 years), vitamin D did not significantly reduce heart attacks, strokes, coronary revascularization or cardiovascular deaths. sources |
| Vitamin E | X | Cardiovascular disease. HOPE (almost 10,000 high-risk patients, 400 IU/day, 4.5 years), Physicians' Health Study II (almost 15,000 men, 8 years) and the Women's Health Study (almost 40,000 women, 10 years) found no reduction in major cardiovascular events. sources |
- A
- Consistent results from several randomized trials or a systematic review of them
- B
- Some positive randomized trials, but small, short, few or inconsistent
- C
- Limited human evidence: single small trials, observational data or mixed results
- D
- Laboratory or animal evidence only; not shown in people
- X
- Well-designed human trials found no meaningful effect
Health information notice
These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.
Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.
EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.